Search clinical trials for: Corticorelin (also known as Acthrel)

Total 193 results

AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie

Completed

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) (ENDURANCE-4)

Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

Chronic Hepatitis C | Hepatitis C Virus | HCV
JANSSEN Alzheimer Immunotherapy Research & Development...
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Alzheimer's Disease

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
Ontario Medical Association
The Behavioural Insights Team

Completed

Supporting the Wellness of Ontario Physicians During COVID-19

Anxiety | Mental Health Wellness 1 | Happiness

Canada
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Hepatitis C Virus (HCV)
Centers for Disease Control and Prevention

Completed

ADAPT-POL New Orleans: Adaptation of Prevention Techniques With Popular Opinion Leader

HIV Infections

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
AstraZeneca

Recruiting

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN)

Prostate Cancer

United States, Spain, United Kingdom, Netherlands, Canada, Australia
Lundquist Institute for Biomedical Innovation at...

Active, not recruiting

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Sleep Restriction

United States
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
ANRS, Emerging Infectious Diseases

Completed

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Hepatitis C
MacroGenics

Completed

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States
AbbVie

Completed

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (ENDURANCE-3)

Chronic Hepatitis C | Hepatitis C Virus | Genotype 3 Hepatitis C Virus
University College, London

Recruiting

Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn (HORACE)

Ornithine Transcarbamylase Deficiency

United Kingdom
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Chronic Hepatitis C | Hepatitis C Virus | HCV | Direct-Acting Antiviral Agent (DAA)-Experienced
ANRS, Emerging Infectious Diseases

Completed

Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection

HIV | Viral Hepatitis C

France
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
University of California, Los Angeles
Bristol-Myers Squibb

Terminated

Abatacept for SLE Arthritis (IM101-330)

Systemic Lupus Erythematosus Arthritis

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Hepatitis C, Chronic
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie
Genentech, Inc.

Completed

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myeloid Leukemia | AML | Acute Myelogenous Leukemia
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Completed

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD) | Significant Memory Concern (SMC) | Early Mild Cognitive Impairment (EMCI) | Late Mild Cognitive Impairment (LMCI)

United States, Canada
Aerovance, Inc.

Completed

A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema

Atopic Eczema

United Kingdom
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Chronic Hepatitis C Infection
Ann & Robert H Lurie Children's Hospital of Chicago
Thrasher Research Fund; Northwestern Memorial Hospital

Unknown

Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns

Staphylococcus Aureus Infection

United States
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)

Chronic Hepatitis C Infection
AbbVie

Terminated

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma (GEODE - I)

Chronic Hepatitis C Infection
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

Chronic Hepatitis C Virus (HCV Infection Genotype 1)
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (MALACHITE 1)

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection (Quartz II/III)

Chronic Hepatitis C Virus Infection
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)

Hepatitis C Virus (HCV)
AbbVie

Completed

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus (HCV)
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

Cirrhosis | Chronic Hepatitis C | Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB)

Decompensated Cirrhosis | Chronic Hepatitis C | Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection (Turquoise-IV)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients (CORAL-I)

Chronic Hepatitis C Infection

3

Subscribe